Pfizer seeks FDA clearance for COVID-19 vaccine in younger children

Pfizer seeks FDA clearance for COVID-19 vaccine in younger children

Pfizer Inc and BioNTech SE on Tuesday asked U.S. health regulators to authorize their COVID-19 vaccine in kids aged 5 to 11.

The application to the U.S. Food and Drug Administration comes as COVID-19 infections have soared in children, hitting their highest point in early September, according to data from the American Academy of Pediatrics.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.